GAINSWave Submits IPO Prospectus: Non-Invasive Shockwave Therapy for Erectile Dysfunction Shows 75% Success Rate

Erectile dysfunction (ED), also known as “impotence,” is a sexual dysfunction characterized by the inability to maintain an erection sufficient in duration for satisfactory sexual intercourse. Due to shame surrounding sexual behaviors, many men are reluctant to report their sexual dysfunction to healthcare providers, resulting in a prevalence of ED that is significantly higher than currently recognized. A study from Johns Hopkins University estimates that more than 18 million men aged 20 and older in the United States suffer from erectile dysfunction.

Currently, the most common treatments for erectile dysfunction are prescription medications such as Viagra and Levitra. These drugs are classified as phosphodiesterase-5 (PDE5) inhibitors, which increase penile blood flow to achieve temporary erections. However, patients may gradually develop dependence on these prescription medications, and long-term use can lead to side effects such as flushing, stomach pain, and dizziness.

The advent of GAINSWave has brought hope to patients with erectile dysfunction (ED). Without the need for medication or surgery, GAINSWave utilizes low-intensity extracorporeal shockwave therapy (Li-ESWT) to stimulate the growth of new blood vessels in the penis and dissolve plaque buildup within existing vessels, thereby increasing penile blood flow and enhancing male sexual performance.

VCBeat (WeChat Official Account: vcbeat) learned from foreign media that on March 9 (U.S. local time), five medical institutions began researching non-invasive solutions for erectile dysfunction (ED), specifically the GAINSWave therapy. These five institutions are Buinewicz Plastic Surgery in Pennsylvania, Genesys Clinic in Utah, Urology Care Center in Illinois, Peak Health Group in California, and Natural Healing Arts Medical Center in Florida.

The near-simultaneous announcement by these five institutions to initiate research on GAINSWave therapy underscores the significant attention this treatment has garnered within the industry, highlighting the substantial unmet medical needs in the field of erectile dysfunction. GAINSWave is a shockwave therapy brand launched by a network of high-quality healthcare providers across China. Currently, the treatment success rate for GAINSWave therapy stands at approximately 75%.

Schematic Diagram of Acoustic Wave Action (Image Source: GAINSWave Official Website)

Any condition that obstructs or restricts blood flow to the two chambers of the penis (the corpora cavernosa) can lead to erectile dysfunction (ED), such as hormonal imbalances, high cholesterol, hypertension, and metabolic syndrome. GAINSWave delivers acoustic wave therapy to ED patients in sessions lasting 15 to 20 minutes each, for a total of 6 to 12 treatment sessions.

GAINSWave stimulates the release of growth factors in penile tissue, promoting angiogenesis; activates dormant stem cells to induce new cell growth; dissolves plaques that restrict blood flow within blood vessels; and fosters the growth of new neural tissue (neurogenesis) in the penis, thereby enhancing penile sensitivity. Furthermore, this therapy can help restore erectile function in patients with erectile dysfunction (ED) who are unresponsive to phosphodiesterase-5 (PDE5) inhibitors, achieving efficacy superior to that of prescription medications without their associated side effects.

Dr. Brian R. Buinewicz of Buinewicz Plastic Surgery led the development of GAINSWave. He stated, “The medical community has long been seeking a core therapy for erectile dysfunction that addresses the underlying condition, rather than merely masking symptoms through painful injections or oral medications. Shockwave therapy has 15 years of clinical application experience in Europe, ranging from successful treatment of plantar fasciitis to ischemic cardiomyopathy. This body of evidence demonstrates that GAINSWave shockwave therapy is the definitive treatment for ED we have been searching for.”

(Compiled by Wang Chan)